Reports from Brussels suggest that European Union anti-trust regulators may fine Ranbaxy for allegedly blocking of entry of cheaper generic medicines in the market.
Reports said that the domestic pharmaceutical company was among the nine companies that are to be fined for the allegedly blocking the entry of the generic medicines in the EU.
When contacted, a Ranbaxy spokesperson said: “We will not like to offer any comments at this point.”
The reports also named Denmark’s Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers.
